查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1756395

基因編輯治療市場，按技術、按開發階段、按治療類型、按疾病適應症、按最終用戶、按國家/地區 - 2025 年至 2032 年全球行業分析、市場規模、市場佔有率及預測

Gene Editing Therapeutics Market, By Technology, By Development Stage, By Therapy Type, By Disease Indication, By End User, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 260 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

報告重點

2024 年基因編輯治療市場規模價值為 1,113 萬美元，2025 年至 2032 年的複合年成長率為 147.20%。

基因編輯治療市場-市場動態

突破性臨床核准和精準工具助力促進治療應用

突破性的臨床核准和精準工具正在顯著推動全球基因編輯療法的應用。美國食品藥物管理局 (FDA) 於 2023 年批准了首個基於 CRISPR 的鐮狀細胞疾病療法，該療法由 Vertex Pharmaceuticals 和 CRISPR Therapeutics 合作開發，標誌著基因編輯向臨床應用邁出了歷史性的一步。同時，美國國立衛生研究院 (NIH) 增加了對精準基因組工程研究的資助，推廣鹼基編輯和主要編輯等工具，以糾正突變並減少脫靶效應。在英國，藥品和保健產品監管局 (MHRA) 已啟動基因編輯療法的加速審查途徑，旨在更快地為患者帶來先進的治療方法。這些發展反映出全球日益重視基因編輯的安全、高效和可擴展的治療應用，增強了其改變遺傳性疾病、癌症和複雜疾病治療的潛力。

基因編輯治療市場—關鍵見解

根據我們的研究分析師的分析，預測期內（2025-2032 年）全球市場年複合成長率預計約為 147.20%。

根據技術細分，預計 CRISPR 將在 2024 年佔據最大市場佔有率

根據開發階段細分，臨床前是 2024 年領先的開發階段

根據治療類型細分，體外基因編輯是 2024 年領先的治療類型

根據疾病適應症細分，遺傳性疾病是 2024 年的主要疾病適應症

根據最終用戶細分，生物製藥公司是 2024 年領先的最終用戶

按地區分類，北美是 2024 年的主要收入來源

基因編輯治療市場-細分分析：

全球基因編輯治療市場根據技術、開發階段、治療類型、疾病適應症、最終用戶和地區進行細分。

根據技術，市場分為五類：CRISPR、ZFN、TALEN、鹼基編輯和RNA編輯。 CRISPR因其簡單高效而處於領先地位；ZFN具有特異性，但設計複雜；TALEN因其在基因敲除研究中的精準靶向性而受到重視；鹼基編輯可實現單核苷酸改變；RNA編輯可在不改變DNA的情況下進行瞬時修飾。

根據開發階段，市場分為五類：臨床前、I期、II期、III期和已獲批准。臨床前階段占主導地位，眾多候選藥物正在研究中；I期側重於安全性分析；II期探索治療效果；III期涉及跨人群的大規模驗證；已獲批准的療法標誌著從研究階段到受監管治療階段的成功過渡，在罕見遺傳疾病領域日益受到關注。

基因編輯治療市場—地理洞察

基因編輯治療市場表現出強勁的區域活力，其中北美由於其先進的生物技術基礎設施、廣泛的臨床研究活動以及來自 FDA 等機構的支持性監管框架而處於領先地位。美國在基於 CRISPR 的療法的核准和試驗方面處於領先地位，這得益於大量公共和私人資金的支持。歐洲緊隨其後，英國、德國和瑞士等國家正積極投資精準醫療，EMA 等監管機構對創新基因治療的接受度也越來越高。亞太地區正在獲得發展動力，尤其是在中國和日本，政府措施和生物技術合作正在加速基因編輯研究。中國積極參與臨床試驗和監管改革正在幫助塑造競爭格​​局。拉丁美洲和中東及非洲正在透過學術合作夥伴關係和試點計畫逐步進入該領域，重點是能力建立和調整監管模式以適應未來的基因治療整合。

基因編輯治療市場-競爭格局：

基因編輯治療市場的競爭格局由許多生技公司、製藥公司和學術研究機構共同塑造，他們致力於推動安全有效的基因編輯療法。領先的參與者正在積極開發基於 CRISPR、TALEN 和鋅指核酸酶 (ZFN) 的療法，以治療多種遺傳疾病和慢性疾病。生技新創公司與大型製藥公司之間的合作日益普遍，旨在加速臨床開發和法規核准。顯著的進展包括合作開發基於 CRISPR 的血液疾病療法和用於癌症的 CAR-T 細胞工程。學術機構也發揮著至關重要的作用，為早期研究和工具改進做出了貢獻，這些工具隨後被授權用於治療用途。獨家授權協議、拓展國際市場以及投資符合 GMP 標準的生產設施等策略性舉措正成為獲得競爭優勢的關鍵，其中重點是開發個人化和治癒性療法。

最新動態：

2025 年 5 月，CRISPR Therapeutics 和 Sirius Therapeutics 宣布進行多目標合作，開發新型 siRNA 療法，包括用於治療血栓栓塞性疾病的 SRSD107，旨在實現一流的、長效的基因治療，減少給藥頻率並改善患者的治療效果。

2025年5月，美國國立衛生研究院（NIH）資助的研究人員為一名患有CPS1缺陷的嬰兒進行了首例個人化CRISPR基因編輯療法。該療法利用一個快速、可自訂的平台，在六個月內糾正了肝細胞中的基因缺陷，標誌著罕見疾病治療領域的突破。

2023年11月，Vertex和CRISPR Therapeutics獲得了全球首個基於CRISPR的鐮狀細胞疾病和BETA地中海貧血基因編輯療法的授權，這是基因編輯療法的歷史性里程碑，為患有這些遺傳疾病的患者帶來了新的希望。

目錄

第1章：基因編輯治療市場概述

  • 研究範圍
  • 市場估計年限

第2章：執行摘要

  • 市場片段
    • 基因編輯治療市場技術片段
    • 基因編輯治療市場依發展階段分類
    • 基因編輯治療市場片段（按治療類型）
    • 基因編輯治療市場片段（按疾病適應症）
    • 基因編輯治療市場片段（按最終用戶）
    • 基因編輯治療市場（按國家/地區）
    • 基因編輯治療市場按地區分類
  • 競爭洞察

第3章：基因編輯治療的關鍵市場趨勢

  • 基因編輯治療市場促進因素
    • 市場促進因素的影響分析
  • 基因編輯治療市場限制
    • 市場限制的影響分析
  • 基因編輯治療市場機遇
  • 基因編輯治療市場未來趨勢

第4章：基因編輯治療產業研究

  • PEST分析
  • 波特五力分析
  • 成長前景圖
  • 規範架構分析

第5章：基因編輯治療市場：地緣政治緊張局勢升級的影響

  • COVID-19 疫情的影響
  • 俄烏戰爭的影響
  • 中東衝突的影響

第6章：基因編輯治療市場格局

  • 2024年基因編輯治療市佔分析
  • 按主要製造商分類的細分數據
    • 成熟玩家分析
    • 新興企業分析

第7章：基因編輯治療市場 - 依技術

  • 概述
    • 按技術細分的市場佔有率分析
    • CRISPR
    • 鋅指蛋白
    • 塔倫
    • 鹼基編輯
    • RNA編輯

第 8 章：基因編輯治療市場 - 依發展階段

  • 概述
    • 按開發階段分類的細分市場佔有率分析
    • 臨床前
    • 第一階段
    • 第二階段
    • 第三階段
    • 得到正式認可的

第9章：基因編輯治療市場－依治療類型

  • 概述
    • 按治療類型分類的細分市場佔有率分析
    • 體內基因編輯
    • 體外基因編輯

第 10 章：基因編輯治療市場 - 依疾病適應症

  • 概述
    • 按疾病適應症分類的細分佔有率分析
    • 血液系統疾病
    • 遺傳性疾病（例如鐮狀細胞疾病、杜氏肌肉營養不良症）
    • 癌症
    • 傳染病
    • 眼部疾病

第 11 章：基因編輯治療市場 - 按最終用戶

  • 概述
    • 按最終用戶細分的佔有率分析
    • 醫院
    • 專科診所
    • 研究機構
    • 生物製藥公司

第 12 章：基因編輯治療市場 - 按地區

  • 介紹
    • 按地區分類的細分市場佔有率分析
  • 北美洲
    • 概述
    • 北美基因編輯治療主要製造商
    • 北美市場規模及預測（按國家/地區）
    • 北美市場規模和預測（按技術）
    • 北美市場規模與預測，依發展階段
    • 北美市場規模和預測，按治療類型
    • 北美市場規模及預測（依疾病類型分類）
    • 北美市場規模和預測（按最終用戶）
    • 美國
    • 加拿大
  • 歐洲
    • 概述
    • 歐洲基因編輯治療主要製造商
    • 歐洲市場規模及預測（按國家/地區）
    • 歐洲市場規模與預測（按技術）
    • 歐洲市場規模及預測（依發展階段）
    • 歐洲市場規模及預測（按治療類型）
    • 歐洲市場規模及預測（依疾病類型分類）
    • 歐洲市場規模和預測（按最終用戶）
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 瑞典
    • 俄羅斯
    • 波蘭
    • 歐洲其他地區
  • 亞太地區 (APAC)
    • 概述
    • 亞太地區基因編輯治療主要製造商
    • 亞太地區市場規模及預測（依國家）
    • 亞太地區市場規模及預測（依技術）
    • 亞太地區市場規模及預測（依發展階段）
    • 亞太地區市場規模及預測（依治療類型）
    • 亞太地區市場規模及預測（依疾病類型分類）
    • 亞太地區市場規模及預測（依最終用戶）
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 印尼
    • 泰國
    • 菲律賓
    • 亞太地區其他地區
  • 拉丁美洲（LATAM）
    • 概述
    • 拉丁美洲基因編輯治療主要製造商
    • 拉丁美洲市場規模及預測（按國家/地區）
    • 拉丁美洲市場規模及預測（按技術）
    • 拉丁美洲市場規模及預測（依發展階段）
    • 拉丁美洲市場規模及預測（按治療類型）
    • 拉丁美洲市場規模及預測（依疾病類型分類）
    • LATAM 規模和預測（按最終用戶）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥倫比亞
    • 拉丁美洲其他地區
  • 中東和非洲
    • 概述
    • 中東和非洲基因編輯治療主要製造商
    • 中東和非洲市場規模及預測（按國家/地區）
    • 中東和非洲市場規模及預測（按技術）
    • 中東及非洲市場規模及預測（依發展階段）
    • 中東和非洲市場規模及預測（按治療類型）
    • 中東和非洲市場規模及預測（按疾病類型分類）
    • 中東和非洲市場規模及預測（按最終用戶）
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 土耳其
    • 阿爾及利亞
    • 埃及
    • MEA 其餘地區

第 13 章：基因編輯治療產業主要供應商分析

  • 競爭儀錶板
    • Competitive Benchmarking
    • Competitive Positioning
  • 公司簡介
    • ArsenalBio
    • Beam Therapeutics
    • Caribou Biosciences
    • CRISPR Therapeutics
    • Editas Medicine
    • EditForce
    • Excision BioTherapeutics
    • Graphite Bio
    • Homology Medicines
    • Intellia Therapeutics
    • LogicBio Therapeutics
    • Poseida Therapeutics
    • Precision BioSciences
    • Recombinetics
    • Sangamo Therapeutics
    • Verve Therapeutics
    • Others

第 14 章：360 度分析師視角

第 15 章：附錄

  • 研究方法
  • 參考
  • 縮寫
  • 免責聲明
  • 聯絡我們
簡介目錄
Product Code: ANV5349

REPORT HIGHLIGHT

Gene Editing Therapeutics Market size was valued at US$ 11.13 Million in 2024, expanding at a CAGR of 147.20% from 2025 to 2032.

The Gene Editing Therapeutics Market centers on the development and commercialization of treatments that correct or modify genetic mutations at the DNA level to treat or potentially cure diseases. With increasing approvals for gene-editing therapies in rare and inherited disorders, the market is expanding into oncology and infectious diseases. In 2023, the U.S. FDA approved the first CRISPR-based therapy for sickle cell anemia, marking a major milestone in clinical gene editing. Technological innovations like base editing and prime editing are enhancing precision while minimizing off-target effects, making gene-editing tools safer for therapeutic use. However, high treatment costs, ethical concerns, and complex regulatory pathways continue to pose significant challenges to widespread adoption. Opportunities exist in the development of personalized medicine, targeting previously untreatable conditions, and expanding gene editing to common diseases, supported by increasing research funding from national health agencies and global biotech collaborations.

Gene Editing Therapeutics Market- Market Dynamics

Breakthrough clinical approvals and precision tools to boost therapeutic adoption

Breakthrough clinical approvals and precision tools are significantly boosting the adoption of gene editing therapeutics worldwide. The U.S. FDA's 2023 approval of the first CRISPR-based therapy for sickle cell disease, developed in partnership with Vertex Pharmaceuticals and CRISPR Therapeutics, marked a historic shift toward clinical application of gene editing. Simultaneously, the National Institutes of Health (NIH) has increased funding for precision genome engineering research, promoting tools like base editing and prime editing to correct mutations with fewer off-target effects. In the UK, the Medicines and Healthcare products Regulatory Agency (MHRA) has initiated accelerated review pathways for gene-editing therapies, aiming to bring advanced treatments to patients faster. These developments reflect a growing global emphasis on safe, efficient, and scalable therapeutic applications of gene editing, reinforcing its potential to transform the treatment of inherited disorders, cancers, and complex diseases.

Gene Editing Therapeutics Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 147.20% over the forecast period (2025-2032)

Based on Technology segmentation, CRISPR was predicted to show maximum market share in the year 2024

Based on Development Stage segmentation, Preclinical was the leading Development Stage in 2024

Based on Therapy Type segmentation, Ex Vivo Gene Editing was the leading Therapy Type in 2024

Based on Disease Indication segmentation, Genetic Disorders were the leading Disease Indication in 2024

Based on end user segmentation, Biopharma Companies was the leading end user in 2024

On the basis of region, North America was the leading revenue generator in 2024

Gene Editing Therapeutics Market- Segmentation Analysis:

The Global Gene Editing Therapeutics Market is segmented on the basis of Technology, Development Stage, Therapy Type, Disease Indication, End User, and Region.

The market is divided into five categories based on Technology: CRISPR, ZFN, TALEN, Base Editing, and RNA Editing. CRISPR leads due to its simplicity and high efficiency; ZFN offers specificity but requires complex design; TALEN is valued for targeting precision in gene knockout studies; base editing enables single-nucleotide changes; RNA editing allows transient modifications without altering DNA.

The market is divided into five categories based on Development Stage: Preclinical, Phase I, Phase II, Phase III, and Approved. Preclinical dominates with numerous candidates under investigation; Phase I focuses on safety profiling; Phase II explores therapeutic efficacy; Phase III involves large-scale validation across populations; Approved therapies mark successful transition from research to regulated treatment, gaining traction in rare genetic disorders.

Gene Editing Therapeutics Market- Geographical Insights

The Gene Editing Therapeutics Market exhibits strong regional dynamics, with North America at the forefront due to advanced biotech infrastructure, extensive clinical research activity, and supportive regulatory frameworks from agencies like the FDA. The U.S. leads in approvals and trials for CRISPR-based therapies, reinforced by substantial public and private funding. Europe follows closely, where countries such as the UK, Germany, and Switzerland are actively investing in precision medicine, and regulatory bodies like the EMA are increasingly receptive to innovative genetic treatments. The Asia-Pacific region is gaining traction, particularly in China and Japan, where government initiatives and biotech collaborations are accelerating gene editing research. China's active involvement in clinical trials and regulatory reforms is helping shape a competitive landscape. Latin America and the Middle East & and Africa are gradually entering the space through academic partnerships and pilot programs, focusing on capacity building and adapting regulatory models for future gene therapy integration.

Gene Editing Therapeutics Market- Competitive Landscape:

The competitive landscape of the Gene Editing Therapeutics Market is shaped by a mix of biotechnology firms, pharmaceutical companies, and academic research institutions striving to advance safe and effective gene-editing therapies. Leading players are actively developing CRISPR, TALEN, and zinc finger nuclease (ZFN)-based treatments, targeting a wide range of genetic and chronic diseases. Collaborations between biotech startups and large pharmaceutical companies are increasingly common, aimed at accelerating clinical development and regulatory approval. Notable advancements include partnerships to co-develop CRISPR-based therapies for blood disorders and CAR-T cell engineering for cancer. Academic institutions also play a vital role, contributing to early-stage research and tool refinement, which are later licensed for therapeutic use. Strategic initiatives such as exclusive licensing agreements, expansion into international markets, and investment in GMP-compliant manufacturing facilities are becoming central to gaining a competitive advantage, with a strong focus on developing personalized and curative therapies.

Recent Developments:

In May 2025, CRISPR Therapeutics and Sirius Therapeutics have announced a multi-target collaboration to develop novel siRNA therapies, including SRSD107 for thromboembolic disorders, aiming for best-in-class, long-acting gene-based treatments with infrequent dosing and improved patient outcomes.

In May 2025, NIH-supported researchers delivered the first personalized CRISPR gene-editing therapy to an infant with CPS1 deficiency. Using a rapid, customizable platform, the treatment corrected the genetic defect in liver cells within six months, marking a breakthrough for rare disease therapeutics.

In November 2023, Vertex and CRISPR Therapeutics received authorization for the world's first CRISPR-based gene editing therapy for sickle cell disease and beta thalassemia, marking a historic milestone in gene editing therapeutics and offering new hope for patients with these genetic disorders.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL GENE EDITING THERAPEUTICS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • ArsenalBio
  • Beam Therapeutics
  • Caribou Biosciences
  • CRISPR Therapeutics
  • Editas Medicine
  • EditForce
  • Excision BioTherapeutics
  • Graphite Bio
  • Homology Medicines
  • Intellia Therapeutics
  • LogicBio Therapeutics
  • Poseida Therapeutics
  • Precision BioSciences
  • Recombinetics
  • Sangamo Therapeutics
  • Verve Therapeutics
  • Others

GLOBAL GENE EDITING THERAPEUTICS MARKET, BY TECHNOLOGY- MARKET ANALYSIS, 2019 - 2032

  • CRISPR
  • ZFN
  • TALEN
  • Base Editing
  • RNA Editing

GLOBAL GENE EDITING THERAPEUTICS MARKET, BY DEVELOPMENT STAGE- MARKET ANALYSIS, 2019 - 2032

  • Preclinical
  • Phase I
  • Phase II
  • Phase III
  • Approved

GLOBAL GENE EDITING THERAPEUTICS MARKET, BY THERAPY TYPE- MARKET ANALYSIS, 2019 - 2032

  • In Vivo Gene Editing
  • Ex Vivo Gene Editing

GLOBAL GENE EDITING THERAPEUTICS MARKET, BY DISEASE INDICATION- MARKET ANALYSIS, 2019 - 2032

  • Hematologic Disorders
  • Genetic Disorders (e.g., Sickle Cell, DMD)
  • Cancer
  • Infectious Diseases
  • Eye Disorders

GLOBAL GENE EDITING THERAPEUTICS MARKET, BY END USER- MARKET ANALYSIS, 2019 - 2032

  • Hospitals
  • Specialty Clinics
  • Research Organizations
  • Biopharma Companies

GLOBAL GENE EDITING THERAPEUTICS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Gene Editing Therapeutics Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Gene Editing Therapeutics Market Snippet by Technology
    • 2.1.2. Gene Editing Therapeutics Market Snippet by Development Stage
    • 2.1.3. Gene Editing Therapeutics Market Snippet by Therapy Type
    • 2.1.4. Gene Editing Therapeutics Market Snippet by Disease Indication
    • 2.1.5. Gene Editing Therapeutics Market Snippet by End User
    • 2.1.6. Gene Editing Therapeutics Market Snippet by Country
    • 2.1.7. Gene Editing Therapeutics Market Snippet by Region
  • 2.2. Competitive Insights

3. Gene Editing Therapeutics Key Market Trends

  • 3.1. Gene Editing Therapeutics Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Gene Editing Therapeutics Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Gene Editing Therapeutics Market Opportunities
  • 3.4. Gene Editing Therapeutics Market Future Trends

4. Gene Editing Therapeutics Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Gene Editing Therapeutics Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Gene Editing Therapeutics Market Landscape

  • 6.1. Gene Editing Therapeutics Market Share Analysis, 2024
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Gene Editing Therapeutics Market - By Technology

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Technology, 2024 & 2032 (%)
    • 7.1.2. CRISPR
    • 7.1.3. ZFN
    • 7.1.4. TALEN
    • 7.1.5. Base Editing
    • 7.1.6. RNA Editing

8. Gene Editing Therapeutics Market - By Development Stage

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Development Stage, 2024 & 2032 (%)
    • 8.1.2. Preclinical
    • 8.1.3. Phase I
    • 8.1.4. Phase II
    • 8.1.5. Phase III
    • 8.1.6. Approved

9. Gene Editing Therapeutics Market - By Therapy Type

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Therapy Type, 2024 & 2032 (%)
    • 9.1.2. In Vivo Gene Editing
    • 9.1.3. Ex Vivo Gene Editing

10. Gene Editing Therapeutics Market - By Disease Indication

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By Disease Indication, 2024 & 2032 (%)
    • 10.1.2. Hematologic Disorders
    • 10.1.3. Genetic Disorders (e.g., Sickle Cell, DMD)
    • 10.1.4. Cancer
    • 10.1.5. Infectious Diseases
    • 10.1.6. Eye Disorders

11. Gene Editing Therapeutics Market - By End User

  • 11.1. Overview
    • 11.1.1. Segment Share Analysis, By End User, 2024 & 2032 (%)
    • 11.1.2. Hospitals
    • 11.1.3. Specialty Clinics
    • 11.1.4. Research Organizations
    • 11.1.5. Biopharma Companies

12. Gene Editing Therapeutics Market- By Geography

  • 12.1. Introduction
    • 12.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
  • 12.2. North America
    • 12.2.1. Overview
    • 12.2.2. Gene Editing Therapeutics Key Manufacturers in North America
    • 12.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.2.4. North America Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 12.2.5. North America Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
    • 12.2.6. North America Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
    • 12.2.7. North America Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
    • 12.2.8. North America Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.2.9. U.S.
      • 12.2.9.1. Overview
      • 12.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.2.9.3. U.S. Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 12.2.9.4. U.S. Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
      • 12.2.9.5. U.S. Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 12.2.9.6. U.S. Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.2.9.7. U.S. Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.2.10. Canada
      • 12.2.10.1. Overview
      • 12.2.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.2.10.3. Canada Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 12.2.10.4. Canada Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
      • 12.2.10.5. Canada Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 12.2.10.6. Canada Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.2.10.7. Canada Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 12.3. Europe
    • 12.3.1. Overview
    • 12.3.2. Gene Editing Therapeutics Key Manufacturers in Europe
    • 12.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.3.4. Europe Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 12.3.5. Europe Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
    • 12.3.6. Europe Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
    • 12.3.7. Europe Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
    • 12.3.8. Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.9. Germany
      • 12.3.9.1. Overview
      • 12.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.9.3. Germany Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 12.3.9.4. Germany Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
      • 12.3.9.5. Germany Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 12.3.9.6. Germany Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.3.9.7. Germany Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.10. UK
      • 12.3.10.1. Overview
      • 12.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.10.3. UK Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 12.3.10.4. UK Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
      • 12.3.10.5. UK Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 12.3.10.6. UK Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.3.10.7. UK Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.11. France
      • 12.3.11.1. Overview
      • 12.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.11.3. France Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 12.3.11.4. France Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
      • 12.3.11.5. France Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 12.3.11.6. France Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.3.11.7. France Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.12. Italy
      • 12.3.12.1. Overview
      • 12.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.12.3. Italy Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 12.3.12.4. Italy Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
      • 12.3.12.5. Italy Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 12.3.12.6. Italy Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.3.12.7. Italy Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.13. Spain
      • 12.3.13.1. Overview
      • 12.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.13.3. Spain Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 12.3.13.4. Spain Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
      • 12.3.13.5. Spain Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 12.3.13.6. Spain Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.3.13.7. Spain Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.14. The Netherlands
      • 12.3.14.1. Overview
      • 12.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.14.3. The Netherlands Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 12.3.14.4. The Netherlands Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
      • 12.3.14.5. The Netherlands Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 12.3.14.6. The Netherlands Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.3.14.7. The Netherlands Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.15. Sweden
      • 12.3.15.1. Overview
      • 12.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.15.3. Sweden Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 12.3.15.4. Sweden Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
      • 12.3.15.5. Sweden Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 12.3.15.6. Sweden Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.3.15.7. Sweden Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.16. Russia
      • 12.3.16.1. Overview
      • 12.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.16.3. Russia Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 12.3.16.4. Russia Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
      • 12.3.16.5. Russia Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 12.3.16.6. Russia Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.3.16.7. Russia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.17. Poland
      • 12.3.17.1. Overview
      • 12.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.17.3. Poland Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 12.3.17.4. Poland Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
      • 12.3.17.5. Poland Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 12.3.17.6. Poland Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.3.17.7. Poland Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.18. Rest of Europe
      • 12.3.18.1. Overview
      • 12.3.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.18.3. Rest of the Europe Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 12.3.18.4. Rest of the Europe Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
      • 12.3.18.5. Rest of the Europe Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 12.3.18.6. Rest of the Europe Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.3.18.7. Rest of the Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 12.4. Asia Pacific (APAC)
    • 12.4.1. Overview
    • 12.4.2. Gene Editing Therapeutics Key Manufacturers in Asia Pacific
    • 12.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.4.4. APAC Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 12.4.5. APAC Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
    • 12.4.6. APAC Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
    • 12.4.7. APAC Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
    • 12.4.8. APAC Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.9. China
      • 12.4.9.1. Overview
      • 12.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.9.3. China Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 12.4.9.4. China Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
      • 12.4.9.5. China Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 12.4.9.6. China Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.4.9.7. China Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.10. India
      • 12.4.10.1. Overview
      • 12.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.10.3. India Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 12.4.10.4. India Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
      • 12.4.10.5. India Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 12.4.10.6. India Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.4.10.7. India Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.11. Japan
      • 12.4.11.1. Overview
      • 12.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.11.3. Japan Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 12.4.11.4. Japan Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
      • 12.4.11.5. Japan Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 12.4.11.6. Japan Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.4.11.7. Japan Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.12. South Korea
      • 12.4.12.1. Overview
      • 12.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.12.3. South Korea Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 12.4.12.4. South Korea Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
      • 12.4.12.5. South Korea Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 12.4.12.6. South Korea Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.4.12.7. South Korea Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.13. Australia
      • 12.4.13.1. Overview
      • 12.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.13.3. Australia Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 12.4.13.4. Australia Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
      • 12.4.13.5. Australia Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 12.4.13.6. Australia Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.4.13.7. Australia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.14. Indonesia
      • 12.4.14.1. Overview
      • 12.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.14.3. Indonesia Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 12.4.14.4. Indonesia Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
      • 12.4.14.5. Indonesia Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 12.4.14.6. Indonesia Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.4.14.7. Indonesia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.15. Thailand
      • 12.4.15.1. Overview
      • 12.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.15.3. Thailand Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 12.4.15.4. Thailand Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
      • 12.4.15.5. Thailand Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 12.4.15.6. Thailand Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.4.15.7. Thailand Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.16. Philippines
      • 12.4.16.1. Overview
      • 12.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.16.3. Philippines Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 12.4.16.4. Philippines Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
      • 12.4.16.5. Philippines Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 12.4.16.6. Philippines Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.4.16.7. Philippines Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.17. Rest of APAC
      • 12.4.17.1. Overview
      • 12.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.17.3. Rest of APAC Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 12.4.17.4. Rest of APAC Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
      • 12.4.17.5. Rest of APAC Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 12.4.17.6. Rest of APAC Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.4.17.7. Rest of APAC Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 12.5. Latin America (LATAM)
    • 12.5.1. Overview
    • 12.5.2. Gene Editing Therapeutics Key Manufacturers in Latin America
    • 12.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.5.4. LATAM Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 12.5.5. LATAM Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
    • 12.5.6. LATAM Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
    • 12.5.7. LATAM Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
    • 12.5.8. LATAM Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.5.9. Brazil
      • 12.5.9.1. Overview
      • 12.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.9.3. Brazil Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 12.5.9.4. Brazil Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
      • 12.5.9.5. Brazil Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 12.5.9.6. Brazil Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.5.9.7. Brazil Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.5.10. Mexico
      • 12.5.10.1. Overview
      • 12.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.10.3. Mexico Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 12.5.10.4. Mexico Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
      • 12.5.10.5. Mexico Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 12.5.10.6. Mexico Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.5.10.7. Mexico Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.5.11. Argentina
      • 12.5.11.1. Overview
      • 12.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.11.3. Argentina Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 12.5.11.4. Argentina Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
      • 12.5.11.5. Argentina Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 12.5.11.6. Argentina Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.5.11.7. Argentina Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.5.12. Colombia
      • 12.5.12.1. Overview
      • 12.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.12.3. Colombia Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 12.5.12.4. Colombia Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
      • 12.5.12.5. Colombia Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 12.5.12.6. Colombia Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.5.12.7. Colombia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.5.13. Rest of LATAM
      • 12.5.13.1. Overview
      • 12.5.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.13.3. Rest of LATAM Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 12.5.13.4. Rest of LATAM Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
      • 12.5.13.5. Rest of LATAM Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 12.5.13.6. Rest of LATAM Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.5.13.7. Rest of LATAM Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 12.6. Middle East and Africa
    • 12.6.1. Overview
    • 12.6.2. Gene Editing Therapeutics Key Manufacturers in Middle East and Africa
    • 12.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.6.4. Middle East and Africa Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 12.6.5. Middle East and Africa Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
    • 12.6.6. Middle East and Africa Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
    • 12.6.7. Middle East and Africa Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
    • 12.6.8. Middle East and Africa Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.6.9. Saudi Arabia
      • 12.6.9.1. Overview
      • 12.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.9.3. Saudi Arabia Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 12.6.9.4. Saudi Arabia Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
      • 12.6.9.5. Saudi Arabia Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 12.6.9.6. Saudi Arabia Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.6.9.7. Saudi Arabia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.6.10. United Arab Emirates
      • 12.6.10.1. Overview
      • 12.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.10.3. United Arab Emirates Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 12.6.10.4. United Arab Emirates Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
      • 12.6.10.5. United Arab Emirates Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 12.6.10.6. United Arab Emirates Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.6.10.7. United Arab Emirates Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.6.11. Israel
      • 12.6.11.1. Overview
      • 12.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.11.3. Israel Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 12.6.11.4. Israel Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
      • 12.6.11.5. Israel Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 12.6.11.6. Israel Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.6.11.7. Israel Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.6.12. Turkey
      • 12.6.12.1. Overview
      • 12.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.12.3. Turkey Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 12.6.12.4. Turkey Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
      • 12.6.12.5. Turkey Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 12.6.12.6. Turkey Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.6.12.7. Turkey Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.6.13. Algeria
      • 12.6.13.1. Overview
      • 12.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.13.3. Algeria Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 12.6.13.4. Algeria Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
      • 12.6.13.5. Algeria Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 12.6.13.6. Algeria Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.6.13.7. Algeria Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.6.14. Egypt
      • 12.6.14.1. Overview
      • 12.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.14.3. Egypt Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 12.6.14.4. Egypt Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
      • 12.6.14.5. Egypt Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 12.6.14.6. Egypt Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.6.14.7. Egypt Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.6.15. Rest of MEA
      • 12.6.15.1. Overview
      • 12.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.15.3. Rest of MEA Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 12.6.15.4. Rest of MEA Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
      • 12.6.15.5. Rest of MEA Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 12.6.15.6. Rest of MEA Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.6.15.7. Rest of MEA Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)

13. Key Vendor Analysis- Gene Editing Therapeutics Industry

  • 13.1. Competitive Dashboard
    • 13.1.1. Competitive Benchmarking
    • 13.1.2. Competitive Positioning
  • 13.2. Company Profiles
    • 13.2.1. ArsenalBio
    • 13.2.2. Beam Therapeutics
    • 13.2.3. Caribou Biosciences
    • 13.2.4. CRISPR Therapeutics
    • 13.2.5. Editas Medicine
    • 13.2.6. EditForce
    • 13.2.7. Excision BioTherapeutics
    • 13.2.8. Graphite Bio
    • 13.2.9. Homology Medicines
    • 13.2.10. Intellia Therapeutics
    • 13.2.11. LogicBio Therapeutics
    • 13.2.12. Poseida Therapeutics
    • 13.2.13. Precision BioSciences
    • 13.2.14. Recombinetics
    • 13.2.15. Sangamo Therapeutics
    • 13.2.16. Verve Therapeutics
    • 13.2.17. Others

14. 360 Degree Analyst View

15. Appendix

  • 15.1. Research Methodology
  • 15.2. References
  • 15.3. Abbreviations
  • 15.4. Disclaimer
  • 15.5. Contact Us